CN1882335A - Hcv感染的组合疗法 - Google Patents

Hcv感染的组合疗法 Download PDF

Info

Publication number
CN1882335A
CN1882335A CNA2004800335847A CN200480033584A CN1882335A CN 1882335 A CN1882335 A CN 1882335A CN A2004800335847 A CNA2004800335847 A CN A2004800335847A CN 200480033584 A CN200480033584 A CN 200480033584A CN 1882335 A CN1882335 A CN 1882335A
Authority
CN
China
Prior art keywords
day
therapeutic combination
dose
achieve
sufficient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800335847A
Other languages
English (en)
Chinese (zh)
Inventor
E·埃特
J·J·阿拉姆
R·S·考夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN1882335A publication Critical patent/CN1882335A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800335847A 2003-10-11 2004-10-12 Hcv感染的组合疗法 Pending CN1882335A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11
US60/510,733 2003-10-11

Publications (1)

Publication Number Publication Date
CN1882335A true CN1882335A (zh) 2006-12-20

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800335847A Pending CN1882335A (zh) 2003-10-11 2004-10-12 Hcv感染的组合疗法

Country Status (17)

Country Link
US (1) US20050112093A1 (enExample)
EP (1) EP1670462A1 (enExample)
JP (1) JP2007508326A (enExample)
KR (1) KR20060120037A (enExample)
CN (1) CN1882335A (enExample)
AR (1) AR045870A1 (enExample)
AU (1) AU2004281747A1 (enExample)
BR (1) BRPI0415249A (enExample)
CA (1) CA2541857A1 (enExample)
IL (1) IL174864A0 (enExample)
MX (1) MXPA06004077A (enExample)
NO (1) NO20062104L (enExample)
PE (1) PE20050477A1 (enExample)
RU (1) RU2006115916A (enExample)
TW (1) TW200528104A (enExample)
WO (1) WO2005037274A1 (enExample)
ZA (1) ZA200602912B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109745315A (zh) * 2019-03-08 2019-05-14 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US20070105781A1 (en) * 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
CN101903392A (zh) * 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
WO2010033443A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
EP2396028A2 (en) * 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
JPWO2011001897A1 (ja) * 2009-06-30 2012-12-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 難治性のｃ型慢性肝炎の治療のための薬剤及び方法
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
KR101991365B1 (ko) * 2017-03-14 2019-06-21 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126674A (en) * 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
BR9910505A (pt) * 1998-05-15 2001-01-02 Schering Corp Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
US20040034206A1 (en) * 2002-05-31 2004-02-19 Schering Corporation Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109745315A (zh) * 2019-03-08 2019-05-14 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Also Published As

Publication number Publication date
BRPI0415249A (pt) 2006-12-12
AU2004281747A1 (en) 2005-04-28
ZA200602912B (en) 2007-06-27
WO2005037274A1 (en) 2005-04-28
PE20050477A1 (es) 2005-08-24
US20050112093A1 (en) 2005-05-26
TW200528104A (en) 2005-09-01
CA2541857A1 (en) 2005-04-28
NO20062104L (no) 2006-05-10
EP1670462A1 (en) 2006-06-21
KR20060120037A (ko) 2006-11-24
IL174864A0 (en) 2008-04-13
JP2007508326A (ja) 2007-04-05
RU2006115916A (ru) 2007-12-10
AR045870A1 (es) 2005-11-16
MXPA06004077A (es) 2006-06-27

Similar Documents

Publication Publication Date Title
CN1882335A (zh) Hcv感染的组合疗法
CN1738635A (zh) 用多阶段干扰素传递曲线治疗肝炎病毒感染的方法
EP1005868A1 (en) Use of alpha interferon and ribavirin in the manufacture of a medicament for combination therapy for chronic hepatitis C infection
CN1271292A (zh) 灭除慢性丙型肝炎感染患者可检测的hcv－rna的联合治疗
CN1217660A (zh) 应用共有干扰素再次治疗丙型肝炎病人的的方法
KR20110054003A (ko) Ｈｃｖ ｎｓ3 프로테아제 억제제와 인터페론 및 리바비린의 병용물
EP2211895A2 (en) Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
CN106535895A (zh) 丁型肝炎病毒感染的治疗
KR20120106942A (ko) Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
JP2006522008A (ja) ウイルス疾患および肝線維症の治療のためのインターフェロン薬物治療
WO2004078127A2 (en) Continuous delivery methods for treating hepatitis virus infection
CN1835765A (zh) 治疗病毒感染的方法
US20150258167A1 (en) New Treatments of Hepatitis C Virus Infection
HK1098359A (en) Combination therapy for hcv infection
CN103221053A (zh) 丙型肝炎病毒感染的新疗法
Zhang Pegylated interferons in the treatment of chronic hepatitis C
JP2014509628A (ja) Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル
WO2008021536A2 (en) Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects
CN1564693A (zh) 治疗肝纤维化和丙型肝炎病毒感染的方法
CN103826654A (zh) 用于治疗丙型肝炎病毒感染的阿拉泊韦
CN103732242A (zh) 用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎
CN103648516A (zh) 使用阿拉泊韦治疗丙型肝炎病毒感染
JP2015509980A (ja) Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098359

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1098359

Country of ref document: HK